ArticleCancers2022

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.

Chau Dang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.